ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Rated Buy in New Coverage at Compass Point

Compass Point initiated coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage issued a buy rating and a $25.00 price target on the stock.

Other research analysts have also recently issued reports about the stock. Weiss Ratings raised shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. Northland Securities initiated coverage on shares of ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They issued an “outperform” rating and a $32.00 price target for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $21.00.

ChronoScale Corporation Common Stock Price Performance

NASDAQ:CHRN opened at $15.08 on Friday. ChronoScale Corporation Common Stock has a 52 week low of $3.50 and a 52 week high of $30.00. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -2.80 and a beta of 0.98. The firm’s 50-day simple moving average is $19.78 and its 200 day simple moving average is $18.23. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.30 and a current ratio of 0.30.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last issued its quarterly earnings data on Wednesday, October 14th. The company reported ($0.29) earnings per share for the quarter. The business had revenue of $41.48 million during the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 66.16% and a negative net margin of 135.66%. As a group, sell-side analysts predict that ChronoScale Corporation Common Stock will post -0.39 earnings per share for the current year.

Institutional Trading of ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc increased its stake in ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the period. Roble Belko & Company Inc owned approximately 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.42% of the company’s stock.

ChronoScale Corporation Common Stock News Roundup

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Compass Point initiated coverage with a Buy rating and a $25 price target, implying approximately 65% upside from the recently quoted $15.15 level. The new coverage may support the stock by adding a bullish view and highlighting potential valuation upside.
• Positive Sentiment: Northland Securities maintained an Outperform rating and a substantially higher $32 price target. Its forecasts anticipate a return to quarterly profitability of $0.16 EPS in Q4 2028, suggesting analysts expect longer-term improvement as ChronoScale scales its AI-focused accelerated-computing platform.
• Neutral Sentiment: ChronoScale reported fiscal first-quarter 2027 results for the period ended August 31, 2026. The results are the most important near-term catalyst, with investors likely focused on revenue growth, losses, cash resources and demand for the company’s AI infrastructure offerings. ChronoScale Reports Fiscal First Quarter 2027 Results
• Negative Sentiment: Despite the optimistic ratings, Northland projects continued losses: $0.39 per share for FY2027 and $0.15 per share for FY2028, with additional quarterly losses expected through Q3 2028. This indicates that the anticipated recovery remains several quarters away.
• Negative Sentiment: ChronoScale’s recent financial profile remains a concern, including negative earnings and margins, a current ratio of 0.51 and a negative return on equity. These factors can keep investors cautious while the company funds growth and works toward profitability. ChronoScale Fiscal Q1 Earnings Snapshot

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.